Jordan Shafran

Jordan Shafran

Auto-generated profile, based on publicly available information

Jordan Shafran

Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KCKiranj Chaudagar
Kiranj Chaudagar
HHHanna M. Hieromnimon
Hanna M. Hieromnimon
RKRimpi Khurana
Rimpi Khurana
BLBrian Labadie
Brian Labadie
THTaghreed Hirz
Taghreed Hirz
APAkash Patnaik
Akash Patnaik
Purpose: Phosphatase and tensin homolog (PTEN) loss of function occurs in approximately 50% of patients with metastatic castrate-resistant prostate cancer (mCRPC), and is associated with poor prognosis and responsiveness to standard-of-care therapies and immune checkpoint inhibitors. While PTEN loss of function hyperactivates PI3K signaling, combinatorial PI3K/AKT pathway and androgen deprivation therapy (ADT) has demonstrated limited anticancer efficacy in clinical trials. Here, we aimed to elucidate mechanism(s) of resistance to ADT/PI3K-AKT axis blockade, and to develop rational combinatorial strategies to effectively treat this molecular subset of mCRPC. Experimental Design: Prostate-specific PTEN/p53-deficient genetically engineered mice (GEM) with established 150–200 mm3 tumors, as assessed by ultrasound, were treated with either ADT (degarelix), PI3K inhibitor (copanlisib), or anti–PD-1 antibody (aPD-1), as single agents or their combinations, and tumors were monitored by MRI and harvested for immune, transcriptomic, and proteomic profiling, or ex vivo co-culture studies. Single-cell RNA sequencing on human mCRPC samples was performed using 10X Genomics platform. Results: Coclinical trials in PTEN/p53-deficient GEM revealed that recruitment of PD-1–expressing tumor-associated macrophages (TAM) thwarts ADT/PI3Ki combination–induced tumor control. The addition of aPD-1 to ADT/PI3Ki combination led to TAM-dependent approximately 3-fold increase in anticancer responses. Mechanistically, decreased lactate production from PI3Ki-treated tumor cells suppressed histone lactylation within TAM, resulting in their anticancer phagocytic activation, which was augmented by ADT/aPD-1 treatment and abrogated by feedback activation of Wnt/β-catenin pathway. Single-cell RNA-sequencing analysis in mCRPC patient biopsy samples revealed a direct correlation between high glycolytic activity and TAM phagocytosis suppression. Conclusions: Immunometabolic strategies that reverse lactate and PD-1–mediated TAM immunosuppression, in combination with ADT, warrant further investigation in patients with PTEN-deficient mCRPC.

23 November 2021 in Science Signaling
Verified
Journal Article
Closed access
NJNaser Jafari
Naser Jafari
MKManohar Kolla
Manohar Kolla
TMTova Meshulam
Tova Meshulam
JSJordan S. Shafran
Jordan S. Shafran
YQYuhan Qiu
Yuhan Qiu
GDGerald V Denis
Gerald V Denis
Exosomes from insulin-resistant adipocytes induce changes in breast cancer cells that promote metastasis.

18 September 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KCKiranj Chaudagar
Kiranj Chaudagar
HHHanna M. Hieromnimon
Hanna M. Hieromnimon
AKAnne Kelley
Anne Kelley
BLBrian Labadie
Brian Labadie
JSJordan Shafran
Jordan Shafran
APAkash Patnaik
Akash Patnaik
Purpose: Phosphatase and tensin homolog (PTEN) loss-of-function/PI3K pathway hyperactivation is associated with poor therapeutic outcomes and immune checkpoint inhibitor resistance across multiple malignancies. Our prior studies in Pb-Cre;PTENfl/flTrp53fl/fl genetically engineered mice (GEM) with aggressive-variant prostate cancer (AVPC) demonstrated tumor growth control in 60% mice following androgen deprivation therapy/PI3K inhibitor (PI3Ki)/programmed cell death protein 1 (PD-1) antibody combination, via abrogating lactate cross-talk between cancer cells and tumor-associated macrophages (TAM), and suppression of histone lactylation (H3K18lac)/phagocytic activation within TAM. Here, we targeted immunometabolic mechanism(s) of PI3Ki resistance, with the goal of durable tumor control in AVPC. Experimental Design: Pb-Cre;PTENfl/flTrp53fl/fl GEM were treated with PI3Ki (copanlisib), MEK inhibitor (trametinib) or Porcupine inhibitor (LGK'974) singly or their combinations. MRI was used to monitor tumor kinetics and immune/proteomic profiling/ex vivo coculture mechanistic studies were performed on GEM tumors or corresponding tumor-derived cell lines. Results: Given our proteomic profiling showing persistent MEK signaling within tumors of PI3Ki-resistant GEM, we tested whether addition of trametinib to copanlisib enhances tumor control in GEM, and we observed 80% overall response rate via additive suppression of lactate within TME and H3K18lac within TAM, relative to copanlisib (37.5%) monotherapy. The 20% resistant mice demonstrated feedback Wnt/β-catenin activation, resulting in restoration of lactate secretion by tumor cells and H3K18lac within TAM. Cotargeting Wnt/β-catenin signaling with LGK'974 in combination with PI3Ki/MEKi, demonstrated durable tumor control in 100% mice via H3K18lac suppression and complete TAM activation. Conclusions: Abrogation of lactate-mediated cross-talk between cancer cells and TAM results in durable ADT-independent tumor control in PTEN/p53-deficient AVPC, and warrants further investigation in clinical trials.

21 July 2020 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
JSJordan S. Shafran
Jordan S. Shafran
NJNaser Jafari
Naser Jafari
ACAllison N. Casey
Allison N. Casey
BGBalázs Győrffy
Balázs Győrffy
GDGerald V Denis
Gerald V Denis

25 November 2025
Verified
Other
Open access
KCKiranj Chaudagar
Kiranj Chaudagar
HHHanna M. Hieromnimon
Hanna M. Hieromnimon
RKRimpi Khurana
Rimpi Khurana
BLBrian Labadie
Brian Labadie
THTaghreed Hirz
Taghreed Hirz
APAkash Patnaik
Akash Patnaik
Supplementary Table S1. ADT + PI3Ki + PD-1 antibody leads to TAM activation within TME of PTEN/p53-deficient prostate tumors.

15 May 2023
Verified
Other
Open access
PDF file
KCKiranj Chaudagar
Kiranj Chaudagar
HHHanna M. Hieromnimon
Hanna M. Hieromnimon
RKRimpi Khurana
Rimpi Khurana
BLBrian Labadie
Brian Labadie
THTaghreed Hirz
Taghreed Hirz
APAkash Patnaik
Akash Patnaik
Supplementary Table S1. ADT + PI3Ki + PD-1 antibody leads to TAM activation within TME of PTEN/p53-deficient prostate tumors.